Want to see DE:RHK full AI Analyst Report?

RHON-KLINIKUM AG (RHK) Price & Analysis

0 Followers

RHK Stock Chart & Stats

€12.90

€0.30(1.99%)

At close: Jan 09 4:00 PM EST

€12.90

€0.30(1.99%)

Day’s Range― - ―

52-Week Range€11.30 - €14.30

Previous CloseN/A

Volume1.17K

Average Volume (3M)955.00

Market Cap

€903.67M

Enterprise Value€802.15M

Total Cash (Recent Filing)€578.26M

Total Debt (Recent Filing)€112.47M

Price to Earnings (P/E)22.5

Beta-0.07

Next Earnings

Aug 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.77%

Share Statistics

EPS (TTM)0.60

Shares Outstanding66,962,470

10 Day Avg. Volume528

30 Day Avg. Volume955

Financial Highlights & Ratios

PEG Ratio-1.22

Price to Book (P/B)0.64

Price to Sales (P/S)0.44

P/FCF Ratio-24.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.76

Revenue Forecast (FY)€1.79B

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthThe company’s low leverage and rising equity provide a durable solvency cushion. Conservative financing supports capital spending, helps withstand reimbursement or demand shocks, and preserves strategic optionality for M&A or restructuring without urgent refinancing.

Reimbursement-backed Revenue BaseRevenue is driven by inpatient, outpatient and ancillary services reimbursed under Germany’s regulated payer system. This creates structurally stable, non-discretionary demand and predictable reimbursement flows that support medium-term revenue resilience.

Proven Historical Cash GenerationOperating cash flow was strong in 2023–24 (€109m–€128m), demonstrating intrinsic cash generation capacity. This historical cash power suggests the business can fund operations and investments when margins normalize, reducing long-term funding risk if the 2025 dip is temporary.

Bears Say

Profitability DeteriorationThe abrupt fall in EBIT (≈€48.1m to ≈€4.4m) indicates meaningful cost pressure or one-off headwinds that erode operating leverage. Given already thin margins, a sustained profit contraction would undermine reinvestment, returns and the company’s ability to absorb future shocks.

Negative Free Cash FlowFree cash flow turned negative (-€34.6m) in 2025 and operating cash flow dropped to €64.5m, reducing internal funding for capex, debt paydown or dividends. If negative FCF persists, RHÖN may need external financing or to cut investment, weakening flexibility.

Revenue Volatility And Thin MarginsRevenue swings across years and a low net margin (~2.7%) show earnings volatility and limited buffer against cost inflation. This pattern complicates medium-term planning, constrains reinvestment, and raises the risk that future reimbursement or cost shocks hit earnings materially.

RHK FAQ

What was RHON-KLINIKUM AG’s price range in the past 12 months?

RHON-KLINIKUM AG lowest stock price was €11.30 and its highest was €14.30 in the past 12 months.

What is RHON-KLINIKUM AG’s market cap?

RHON-KLINIKUM AG’s market cap is €903.67M.

When is RHON-KLINIKUM AG’s upcoming earnings report date?

RHON-KLINIKUM AG’s upcoming earnings report date is Aug 06, 2026 which is in 23 days.

How were RHON-KLINIKUM AG’s earnings last quarter?

RHON-KLINIKUM AG released its earnings results on May 07, 2026. The company reported €0.19 earnings per share for the quarter, beating the consensus estimate of N/A by €0.19.

Is RHON-KLINIKUM AG overvalued?

According to Wall Street analysts RHON-KLINIKUM AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does RHON-KLINIKUM AG pay dividends?

RHON-KLINIKUM AG pays a Annually dividend of €0.2 which represents an annual dividend yield of 0.77%. See more information on RHON-KLINIKUM AG dividends here

What is RHON-KLINIKUM AG’s EPS estimate?

RHON-KLINIKUM AG’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does RHON-KLINIKUM AG have?

RHON-KLINIKUM AG has 66,962,470 shares outstanding.

What happened to RHON-KLINIKUM AG’s price movement after its last earnings report?

RHON-KLINIKUM AG reported an EPS of €0.19 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of RHON-KLINIKUM AG?

Currently, no hedge funds are holding shares in DE:RHK

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

RHON-KLINIKUM AG Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

3.04%

Trailing 12-Months

Asset Growth

-1.58%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

RHON-KLINIKUM AG

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, delivers extensive healthcare services across Germany, encompassing inpatient, day-patient, and outpatient treatment models. The company's hospitals provide a broad spectrum of medical and surgical care, including cardiovascular rehabilitation, specialized hand and trauma surgery, neurological and psychosomatic treatments, addiction therapy, ophthalmology, and dentistry. They also address conditions affecting the thoracic region, lungs, and vascular system, offer oncology services, and manage neurological conditions, spinal column and joint issues, as well as heart diseases. The organization operates eight hospitals, providing a total of 5,420 beds or patient slots across five distinct medical locations. RHÖN-KLINIKUM is headquartered in Bad Neustadt an der Saale, Germany.